美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,222.30

-28.9442-2.31%

涨家数：3

跌家数：4

平家数：- -

市盈率：- -

高：1,257.62

开：1,252.13

低：1,216.60

收：1,251.24

数据加载中...

蒙特利尔银行：将辉瑞（PFE.N）目标价从36美元下调至30美元。

礼来(LLY.N)盘前大涨13%，此前其发布了减肥药研究数据。

辉瑞4月16日成交额为8.36亿美元

诺和诺德4月16日成交额为4.00亿美元

礼来4月16日成交额为24.37亿美元

辉瑞：CDC建议将呼吸道合胞病毒疫苗扩大到年轻人。

【欧股“十一罗汉”收盘播报｜阿斯麦收跌约5.2%，诺和诺德跌超1%】周三，阿斯麦控股荷兰阿姆斯特丹股价收跌5.19%，报574.00欧元。诺和诺德哥本哈根股价收跌1.03%，报421.30。赛诺菲跌1.34%，LVMH集团、欧莱雅、罗氏制药、阿斯利康、德国思爱普Sap、葛兰素史克跌0.71%-0.04%，诺华和雀巢分别涨0.29%和0.49%。此外，半导体概念股普遍收跌，除阿斯麦控股之外，BE半导体实业和ASM国际至多跌3.2%，Soitec、德国爱思强、意法半导体跌1.85%-1.31%，英飞凌也跌0.96%。

硕迪生物盘中异动股价大跌5.03%

因受试者出现肝损伤项目终止辉瑞减肥药研发再遇挫

礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理

智通财经网

辉瑞、礼来新适应症在华报产！康弘Trop2-ADC崭露头角

医药经济报

文件显示，沃尔玛与钦奈办事处达成交易，提升在印度的科技影响力

辉瑞被减肥药“搞怕了”

Ofweek维科网

辉瑞4月15日成交额为11.68亿美元

诺和诺德4月15日成交额为3.85亿美元

礼来4月15日成交额为18.62亿美元

安进4月15日成交额为7.64亿美元

联邦制药(3933.HK)：UBT251授权给诺和诺德创新转型初见成效

辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury

诺和诺德盘中异动大幅下挫3.01%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4599/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1222.2908,"timestamp":1745263517006,"preClose":1251.235,"halted":0,"volume":44063095,"delay":0,"changeRate":-0.023133,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-28.944214,"latestTime":"04-21 15:25:17 EDT","open":1252.1276,"high":1257.6151,"low":1216.6044,"amount":3651191840.283778,"amplitude":0.032776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.286466,"peRate":32.45662,"turnoverRate":0.004171,"increases":3,"decrements":4,"flats":0,"marketCap":1303011393440,"floatMarketCap":1227388849952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1257.6151,"amplitude":0.032776,"preClose":1251.235,"low":1216.6044,"pbRate":"9.286466","latestPrice":1222.304,"volume":44063386,"delay":0,"open":1252.1276,"prevYearClose":1305.0607,"prevWeekClose":1251.235,"prevMonthClose":1314.3724,"prevQuarterClose":1314.3724,"fiveDayClose":1177.7317,"twentyDayClose":1358.6935,"sixtyDayClose":1290.7499,"secType":"PLATE","market":"US","turnoverRate":0.004171,"peRate":32.45662,"marketCap":1303011393440,"floatMarketCap":1227388849952,"timestamp":1745263518145,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528718414","title":"蒙特利尔银行：将辉瑞（PFE.N）目标价从36美元下调至30美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718414","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718414?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 19:23","pubTimestamp":1744889039,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4592","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","SG9999011175.SGD","IE00B19Z3581.USD","BK4588","LU0456855351.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4581","IE0002270589.USD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4550","LU0985481810.HKD","PFE","SG9999001176.USD","IE00BBT3K403.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0170899867.USD","LU1066051498.USD","LU0058720904.USD","BK4599","BK4585","LU1023059063.AUD","SG9999001176.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","BMO","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","BK4568","LU0868494617.USD","BK4533","BK4207","LU1894683348.USD","LU0321505868.SGD","LU1883839398.USD","BK4007","LU1057294990.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2528379793","title":"礼来(LLY.N)盘前大涨13%，此前其发布了减肥药研究数据。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528379793","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528379793?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 18:52","pubTimestamp":1744887142,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"17136e9096e01d550821b3b9313a36c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4534","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0122379950.USD","LU0943347566.SGD","LU0097036916.USD","LU0708995401.HKD","SGXZ57979304.SGD","LU0471298694.HKD","LU1974910355.USD","LU2023250504.SGD","LU1057294990.SGD","LLY","IE00B1BXHZ80.USD","LU1061106388.HKD","LU0823416689.USD","LU1868836757.USD","LU2237443382.USD","LU1093756325.SGD","IE0004445239.USD","LU1868837136.USD","LU0320765059.SGD","LU0689472784.USD","LU0106261372.USD","SG9999015986.USD","LU1720051017.SGD","BK4533","LU2552382132.HKD","LU0061475181.USD","LU0466842654.USD","LU2264538146.SGD","LU2237443622.USD","LU2237443549.SGD","LU0882574139.USD","SG9999018857.SGD","LU2552382058.USD","LU0820561909.HKD","LU0203201768.USD","SG9999014880.SGD","LU1868836914.USD","LU2552382215.SGD","LU1868836591.USD","LU0289739699.SGD","BK4599","LU2237438978.USD","LU2237443978.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1868837300.USD","LU0203202063.USD"],"gpt_icon":0},{"id":"2528873881","title":"辉瑞4月16日成交额为8.36亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528873881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528873881?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 10:16","pubTimestamp":1744856184,"startTime":"0","endTime":"0","summary":"美东时间2025年4月16日，辉瑞成交额为8.36亿美元，成交额较昨日减少28.41%，当日成交量为3764.12万股。辉瑞于2025年4月16日跌1.78%，报22.04美元，该股过去5个交易日跌2.0%，年初至今跌15.55%，过去60日跌15.9%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-16|8.36亿|-28.41%|3764.12万|#|2025-04-15|11.68亿|-14.48%|5181.47万|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417101627a45bd947&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417101627a45bd947&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","LU0306807586.USD","PFE","LU1066053197.SGD","LU1894683264.USD","LU1066051498.USD","SG9999013999.USD","IE00BLSP4452.SGD","BK4568","IE000M9KFDE8.USD","BK4599","SG9999002232.USD","LU0321505439.SGD","BK4534","LU0170899867.USD","LU0321505868.SGD","LU0225771236.USD","LU1883839398.USD","LU0306806265.USD","IE0002270589.USD","SG9999001176.USD","LU0225284248.USD","BK4592","BK4007","BK4533","IE00B19Z3B42.SGD","LU1023059063.AUD","SG9999011175.SGD","LU1057294990.SGD","LU0868494617.USD","BK4588","SG9999003800.SGD","BK4585","IE00BLSP4239.USD","LU0122379950.USD","LU1894683348.USD","BK4581","SGXZ57979304.SGD","LU0456855351.SGD","LU0234572021.USD","LU0058720904.USD","LU0289739699.SGD","SG9999002224.SGD","SG9999001176.SGD","LU0985481810.HKD","BK4550","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2528738993","title":"诺和诺德4月16日成交额为4.00亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528738993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528738993?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 10:10","pubTimestamp":1744855821,"startTime":"0","endTime":"0","summary":"美东时间2025年4月16日，诺和诺德成交额为4.00亿美元，成交额较昨日增加3.93%，当日成交量为630.26万股。诺和诺德于2025年4月16日跌2.5%，报62.88美元，该股过去5个交易日跌3.4%，年初至今跌26.03%，过去60日跌21.47%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417101030a45bd786&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417101030a45bd786&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","IE00BKVL7J92.USD","BK4532","BK4585","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","NVO","BK4007","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":1},{"id":"2528787721","title":"礼来4月16日成交额为24.37亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528787721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528787721?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 09:50","pubTimestamp":1744854627,"startTime":"0","endTime":"0","summary":"美东时间2025年4月16日，礼来成交额为24.37亿美元，成交额较昨日增加30.87%，当日成交量为330.26万股。礼来于2025年4月16日跌2.94%，报734.9美元，该股过去5个交易日跌2.5%，年初至今跌4.64%，过去60日跌0.83%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-16|24.37亿|30.87%|330.26万|#|2025-04-15|18.62亿|-28.31%|245.81万|#|2025-04-14|25.98亿|-0.95%|346.12万|#|2025-04-11|26.23亿|-12.56%|360.34万|#|2025-04-10|29.99亿|-37.21%|418.27万|礼来制药公司是一家专注于神经科学、心脏代谢、癌症和免疫学的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417095029a6bd45ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417095029a6bd45ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0096364046.USD","LU0203201768.USD","BK4585","LU1064131342.USD","LU1093756325.SGD","LU2023250504.SGD","LU2357305700.SGD","LU2491050071.SGD","LU0256863902.USD","SG9999014906.USD","LU0689472784.USD","LU2461242641.AUD","LU1291159041.SGD","LU0943347566.SGD","LU1814569148.SGD","LU1983299246.USD","IE00B4R5TH58.HKD","LU0106261372.USD","LU1023059063.AUD","BK4533","LU1232071149.USD","LLY","SGXZ57979304.SGD","LU2237443382.USD","LU2211815571.USD","GB00BDT5M118.USD","LU1623119135.USD","LU0471298694.HKD","LU1720051017.SGD","SG9999001176.USD","LU0079474960.USD","LU0198837287.USD","LU1548497426.USD","BK4599","LU2237443895.HKD","LU2089984988.USD","SGXZ51526630.SGD","SG9999014914.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU1712237335.SGD","SG9999014898.SGD","LU2552382058.USD","IE00BK4W5L77.USD","LU2360106947.USD","LU2491049909.HKD","LU1974910355.USD","LU0820561818.USD","LU2471134879.HKD","LU2750360997.AUD"],"gpt_icon":1},{"id":"2528080752","title":"辉瑞：CDC建议将呼吸道合胞病毒疫苗扩大到年轻人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080752","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528080752?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 04:33","pubTimestamp":1744835634,"startTime":"0","endTime":"0","summary":"辉瑞：CDC建议将呼吸道合胞病毒疫苗扩大到年轻人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/17043349604117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0306806265.USD","LU1023059063.AUD","LU0985481810.HKD","CDC","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","LU1057294990.SGD","BK4533","PFE","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4599","BK4568","SG9999002224.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","BK4534","LU0321505439.SGD","LU0234572021.USD","LU0306807586.USD","SG9999013999.USD","LU1066053197.SGD","LU0868494617.USD","BK4007","LU1066051498.USD","159646","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1894683264.USD","BK4588","LU0321505868.SGD","IE0002270589.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4585","LU0225284248.USD"],"gpt_icon":0},{"id":"2528222859","title":"【欧股“十一罗汉”收盘播报｜阿斯麦收跌约5.2%，诺和诺德跌超1%】 周三，阿斯麦控股荷兰阿姆斯特丹股价收跌5.19%，报574.00欧元。诺和诺德哥本哈根股价收跌1.03%，报421.30。赛诺菲跌1.34%，LVMH集团、欧莱雅、罗氏制药、阿斯利康、德国思爱普Sap、葛兰素史克跌0.71%-0.04%，诺华和雀巢分别涨0.29%和0.49%。此外，半导体概念股普遍收跌，除阿斯麦控股之外，BE半导体实业和ASM国际至多跌3.2%，Soitec、德国爱思强、意法半导体跌1.85%-1.31%，英飞凌也跌0.96%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528222859","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528222859?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 00:37","pubTimestamp":1744821436,"startTime":"0","endTime":"0","summary":"周三，阿斯麦控股荷兰阿姆斯特丹股价收跌5.19%，报574.00欧元。诺和诺德哥本哈根股价收跌1.03%，报421.30。赛诺菲跌1.34%，LVMH集团、欧莱雅、罗氏制药、阿斯利康、德国思爱普Sap、葛兰素史克跌0.71%-0.04%，诺华和雀巢分别涨0.29%和0.49%。此外，半导体概念股普遍收跌，除阿斯麦控股之外，BE半导体实业和ASM国际至多跌3.2%，Soitec、德国爱思强、意法半导体跌1.85%-1.31%，英飞凌也跌0.96%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/17003749603707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4532","BK4543","ASM","GSK","LU1734074674.USD","BK1574","BK4554","IE00B4R5TH58.HKD","LU2506951792.HKD","STM","LU2249611893.SGD","BK4568","LU0823434740.USD","NVS","LU0345774631.USD","IE00BD6J9T35.USD","LU0097036916.USD","BE","01477","IE0004445239.USD","LU0320765489.SGD","IE0009355771.USD","BK4541","GSK.UK","LU0889565916.HKD","LU2063271972.USD","BK4585","LU0211331839.USD","LU1642822529.SGD","AZN","IE00BZ1G4Q59.USD","LU0823414478.USD","LU0208291251.USD","LU0320765992.SGD","BK4599","BK4212","NSRGY","BK4578","LU0823434583.USD","BK4588","ASML","BK4604","BK4141","LU1093756168.USD","BK1191","BK4188","NVO","03165","LRLCY","159582"],"gpt_icon":0},{"id":"2527365244","title":"硕迪生物盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527365244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527365244?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 22:17","pubTimestamp":1744813065,"startTime":"0","endTime":"0","summary":"北京时间2025年04月16日22时17分，硕迪生物股票出现波动，股价急速跳水5.03%。截至发稿，该股报17.95美元/股，成交量10.3313万股，换手率0.18%，振幅4.36%。机构评级方面，在所有13家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为1.53%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416221746a6bcadb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416221746a6bcadb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2527245520","title":"因受试者出现肝损伤项目终止 辉瑞减肥药研发再遇挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2527245520","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527245520?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 21:33","pubTimestamp":1744810415,"startTime":"0","endTime":"0","summary":"在当下正热的胰高糖素样肽-1受体激动剂（GLP-1）药物领域，美国制药巨头辉瑞似乎缺少了一些运气。当地时间4月14日，辉瑞宣布终止口服GLP-1受体激动剂Danuglipron的研发，该药物此前被开发用于慢性体重管理。辉瑞此前已终止口服GLP-1候选药物Lotiglipon（每日一次）的开发，目前仅剩一款口服GIPR拮抗剂处于二期临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504163378947287.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504163378947287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1057294990.SGD","SG9999003800.SGD","LU1066053197.SGD","PFE","LU1023059063.AUD","SG9999002232.USD","BK4568","IE00B19Z3B42.SGD","LU0234572021.USD","BK4581","LU0321505868.SGD","LU1066051498.USD","BK4585","LU0868494617.USD","LU1883839398.USD","BK4588","IE00BLSP4239.USD","BK4599","LU0122379950.USD","LU0225284248.USD","SG9999001176.USD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4534","SGXZ57979304.SGD","SG9999002224.SGD","LU0306807586.USD","BK4533","LU0289739699.SGD","LU0306806265.USD","LU0985481810.HKD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0225771236.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE0002270589.USD","LU1894683264.USD","BK4007","LU1894683348.USD","LU0058720904.USD","BK4550","SG9999013999.USD","BK4592","LU0170899867.USD","LU0321505439.SGD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2527532245","title":"礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2527532245","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527532245?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 21:13","pubTimestamp":1744809180,"startTime":"0","endTime":"0","summary":"今日，中国国家药监局药品审评中心官网最新公示，礼来公司申报的米吉珠单抗注射液以及其皮下注射剂型的新适应症上市申请获得受理。截图来源：CDE官网米吉珠单抗是一款人源化IgG4单克隆抗体，可与IL-23的p19亚基结合，阻断IL-23介导的炎症反应。根据礼来此前新闻稿，这是首个用于治疗这一患者群体的IL-23p19拮抗剂。2025年1月，米吉珠单抗再次获FDA批准，用于治疗成人中度至重度活动性克罗恩病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetkpat4324726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0203201768.USD","LU0203202063.USD","LU2106854487.HKD","LU2552382215.SGD","LU1267930730.SGD","LU0708995401.HKD","SG9999015986.USD","LU1720051108.HKD","BK4599","LU2237443895.HKD","LU0109391861.USD","LU2750360997.AUD","LU2265009873.SGD","LU0096364046.USD","GB00BDT5M118.USD","LU1093756168.USD","SGXZ31699556.SGD","LU0640476718.USD","LU2089984988.USD","BK4017","LU2237438978.USD","LU0061475181.USD","LU1366192091.USD","LU0354030438.USD","LU2361045086.USD","LU2750360641.GBP","LU2357305700.SGD","BK4534","LU0238689110.USD","SGXZ99366536.SGD","LU0256863902.USD","SGXZ51526630.SGD","LU1720051017.SGD","LLY","LU0320765059.SGD","LU2491050071.SGD","LU2461242641.AUD","CDEDC","SG9999015952.SGD","CDE","LU2471134796.USD","SG9999018865.SGD","LU2468319806.SGD","LU0471298777.SGD","LU0114720955.EUR","LU0354030511.USD","BK4533","LU2491050154.USD","LU1280957306.USD","SG9999001176.USD","LU2491049909.HKD"],"gpt_icon":1},{"id":"2527297956","title":"辉瑞、礼来新适应症在华报产！康弘Trop2-ADC崭露头角","url":"https://stock-news.laohu8.com/highlight/detail?id=2527297956","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527297956?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 19:06","pubTimestamp":1744801572,"startTime":"0","endTime":"0","summary":"辉瑞 PARP 抑制剂新适应症在华申报上市今日，CDE官网显示，辉瑞制药的甲苯磺酸他拉唑帕利胶囊新适应症上市申请获受理。根据注册分类以及临床试验进展推测，此次申报的适应症为胚系 BRCA突变的HER2阴性乳腺癌。根据公开资料推测，本次该药申报上市的适应症为治疗中重度活动性溃疡性结肠炎成人患者。根据礼来此前新闻稿，这是首个用于治疗这一患者群体的IL-23p19拮抗剂。此外，礼来已于2024年10月公布了多年期的Ⅲ期试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416191552a6bc81e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416191552a6bc81e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999017495.SGD","LU2750360641.GBP","SG9999014898.SGD","LU0868494617.USD","LU1894683264.USD","ADC","LU1868837300.USD","LU1232071149.USD","SG9999018857.SGD","LU0823416689.USD","LU1057294990.SGD","LU0234572021.USD","SGXZ99366536.SGD","LU2468319806.SGD","LU0882574139.USD","PFE","IE00BJT1NW94.SGD","LU0058720904.USD","LU0256863902.USD","LU2361044865.SGD","LU0456855351.SGD","LU2361045086.USD","BK4599","LU1917777945.USD","LU0985481810.HKD","LU2552382132.HKD","LU0354030511.USD","LU2491049909.HKD","SG9999015986.USD","LU1868836757.USD","SG9999014906.USD","LU0672654240.SGD","LU0122379950.USD","LU2237443382.USD","LU2211815571.USD","IE0002270589.USD","LU0689472784.USD","LU0114720955.EUR","IE00BBT3K403.USD","LU2471134523.USD","LU1974910355.USD","LU0943347566.SGD","LU0385154629.USD","LLY","LU0417517546.SGD","LU1868837136.USD","LU1548497426.USD","LU1720051017.SGD","LU1894683348.USD","LU2237443549.SGD"],"gpt_icon":1},{"id":"2527291392","title":"文件显示，沃尔玛与钦奈办事处达成交易，提升在印度的科技影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=2527291392","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527291392?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 18:51","pubTimestamp":1744800703,"startTime":"0","endTime":"0","summary":"路透班加罗尔4月16日 - 沃尔玛WMT.N在印度南部城市钦奈签署了第二个办公空间的协议，钦奈在作为制造业中心闻名多年后，正迅速崛起为一个重要的技术中心。据路透周三看到的一份文件显示，沃尔玛已经租下了超过465,000平方英尺的面积，最初租期为5年，从今年11月开始。尽管沃尔玛尚未在印度经营超市，但它在钦奈和班加罗尔等城市设有技术办事处。沃尔玛没有立即回应路透的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4T3QU0T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","LU1481599808.USD","LU0175139822.USD","LU0496365809.HKD","LU2133065610.SGD","LU1267930227.SGD","LU2360032135.SGD","LU1153584641.USD","LU0499090636.EUR","LU0211327993.USD","BK4599","03165","LU0203345920.USD","LU0077335932.USD","LU2112291526.USD","LU1066053197.SGD","LU1066051811.HKD","LU2264538146.SGD","IE0002141913.USD","LU2097829019.USD","IE00B7KXQ091.USD","IE00BJJMRX11.SGD","LU1035773651.USD","LU1366192091.USD","LU0868494617.USD","IE0034235188.USD","IE00B7SZLL34.SGD","LU1064131342.USD","LU0211328371.USD","LU0256863902.USD","LU1119994496.HKD","IE0004445015.USD","LU0170899867.USD","LU1814569148.SGD","LU2108987350.USD","LU2471134879.HKD","LU0211326755.USD","LU1057294990.SGD","LU0545039389.USD","AZN.UK","LU0882574055.USD","LU0784384876.USD","IE00B4R5TH58.HKD","LU2430703251.USD","LU1894683348.USD","WMT","UPS","LU1066051225.USD","IE000M9KFDE8.USD"],"gpt_icon":1},{"id":"2527123178","title":"辉瑞被减肥药“搞怕了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527123178","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527123178?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 13:53","pubTimestamp":1744782824,"startTime":"0","endTime":"0","summary":"辉瑞决定取消Danuglipron的研发，核心原因在于，有1名患者可能受到药物诱导的肝损伤。2023年末，辉瑞公布Danuglipron治疗肥胖2b期临床的最新数据。市场认为，辉瑞遭遇打击之后，可能会继续收购减肥药资产，属于Viking们的机会来了。辉瑞并没有彻底放弃减肥药资产，目前其布局的管线中，一种口服小分子GIPR拮抗剂，处于2期开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4599","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","LU0234572021.USD","IE0002270589.USD","LU0456855351.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","BK4533","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4550","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","BK4585","LU1023059063.AUD","SGXZ57979304.SGD","LU0225771236.USD"],"gpt_icon":1},{"id":"2527288993","title":"辉瑞4月15日成交额为11.68亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527288993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527288993?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 10:13","pubTimestamp":1744769630,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，辉瑞成交额为11.68亿美元，成交额较昨日减少14.48%，当日成交量为5181.47万股。辉瑞于2025年4月15日涨1.45%，报22.44美元，该股过去5个交易日涨2.75%，年初至今跌14.02%，过去60日跌13.26%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-15|11.68亿|-14.48%|5181.47万|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|#|2025-04-09|20.87亿|30.20%|9595.44万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2527270288","title":"诺和诺德4月15日成交额为3.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527270288","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527270288?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 10:07","pubTimestamp":1744769277,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，诺和诺德成交额为3.85亿美元，成交额较昨日减少27.86%，当日成交量为594.56万股。诺和诺德于2025年4月15日跌2.38%，报64.49美元，该股过去5个交易日涨4.69%，年初至今跌24.13%，过去60日跌17.07%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100804a45a7382&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100804a45a7382&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","LU1093756168.USD","BK4007","BK4588","BK4599","NVO","BK4532","IE00BKVL7J92.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2527407051","title":"礼来4月15日成交额为18.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527407051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527407051?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:48","pubTimestamp":1744768096,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，礼来成交额为18.62亿美元，成交额较昨日减少28.31%，当日成交量为245.81万股。礼来于2025年4月15日涨0.38%，报757.18美元，该股过去5个交易日涨4.26%，年初至今跌1.75%，过去60日涨4.51%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-15|18.62亿|-28.31%|245.81万|#|2025-04-14|25.98亿|-0.95%|346.12万|#|2025-04-11|26.23亿|-12.56%|360.34万|#|2025-04-10|29.99亿|-37.21%|418.27万|#|2025-04-09|47.77亿|57.32%|661.90万|礼来制药公司是一家专注于神经科学、心脏代谢、癌症和免疫学的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416094825a6bbeaf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416094825a6bbeaf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1127390331.HKD","SG9999014906.USD","LU2471134796.USD","LU1983299246.USD","LU1917777945.USD","LU1720051108.HKD","LU0943347566.SGD","LU2552382132.HKD","LU2237443465.HKD","LU1551013425.SGD","LU0198837287.USD","LU0203202063.USD","LU2471134523.USD","LU0122379950.USD","BK4599","LU0203201768.USD","LU0466842654.USD","LU2491049909.HKD","LU2237438978.USD","IE00B2B36J28.USD","LU0079474960.USD","LU2361044949.HKD","LU0471298694.HKD","LU0114720955.EUR","SG9999014898.SGD","LU2089984988.USD","BK4585","SG9999014914.USD","LLY","SG9999013999.USD","LU1267930730.SGD","BK4516","LU2461242641.AUD","LU2361045086.USD","LU0385154629.USD","LU0417517546.SGD","LU0456855351.SGD","LU2360106947.USD","LU2471134879.HKD","LU2468319806.SGD","SG9999001176.SGD","LU0096364046.USD","LU1868837300.USD","IE00BK4W5M84.HKD","LU2602419157.SGD","LU0061475181.USD","SG9999015978.USD","SG9999018857.SGD","LU0320765059.SGD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2527409934","title":"安进4月15日成交额为7.64亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527409934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527409934?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:15","pubTimestamp":1744766148,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，安进成交额为7.64亿美元，成交额较昨日增加4.95%，当日成交量为259.36万股。安进于2025年4月15日涨0.47%，报295.3美元，该股过去5个交易日涨5.37%，年初至今涨14.21%，过去60日涨9.4%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091610a45a622e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091610a45a622e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU0868494617.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","AMGN","LU2242652126.USD","SG9999001440.SGD","LU1057294990.SGD","BK4139","LU1571399168.USD","BK4534","LU2468319806.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0058720904.USD","IE0009355771.USD","LU2242646821.SGD","LU0109394709.USD","BK4599","LU0289739699.SGD","BK4566","LU0889565916.HKD","LU0122379950.USD","BK4588","BK4585","IE0002141913.USD","BK4581","BK4533","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1983299246.USD"],"gpt_icon":0},{"id":"2527403040","title":"联邦制药(3933.HK)：UBT251授权给诺和诺德 创新转型初见成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2527403040","media":"第一上海","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527403040?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 08:01","pubTimestamp":1744761717,"startTime":"0","endTime":"0","summary":"生物药管线：利拉鲁肽25 年获批上市，德谷胰岛素26 年上市，司美格鲁肽糖尿病适应症报产，减重适应症进入临床三期；UBT251与诺和诺德达成授权合作，首付款2亿美元，潜在里程碑款18 亿美元。综上所述，25 年叠加UBT251首付款，公司整体收入及利润端有望稳中有升。24 年司美格鲁肽收入同比增长38%至293 亿美元。而礼来的替而泊肽SURMOUNT - 1 试验显示其15mg 剂量组72 周平均减重 20.9%。而UBT251 在1b 临床试验中显示其12 周即可以达到15.1%的降幅，具有潜在Best in Class 的可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416080159a45a520c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416080159a45a520c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","IE00BKVL7J92.USD","BK4532","BK4585","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","NVO","BK4007","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":1},{"id":"2527425919","title":"辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425919","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425919?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 01:35","pubTimestamp":1744738500,"startTime":"0","endTime":"0","summary":"Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.辉瑞将停止对丹纳格列波隆的所有测试，包括其与其他药物联合用于肥胖症治疗的测试。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期价格有所下调，许多此类药物每月的费用仍高达数百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.辉瑞公司已于 2023 年底停止了每日两次服用的丹那列普隆的测试，当时试验中超过一半的人已停止服用该药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4452.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4592","LU0225771236.USD","LU1023059063.AUD","LU1066051498.USD","LU0122379950.USD","BK4581","LU0456855351.SGD","BK4588","LU0058720904.USD","BK4599","IE0002270589.USD","LU0306806265.USD","PFE","LU0321505439.SGD","BK4568","LU1057294990.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","IE00B19Z3581.USD","BK4585","LU1894683348.USD","LU0170899867.USD","LU1883839398.USD","LU0985481810.HKD","SG9999001176.USD","SGXZ57979304.SGD","LU1894683264.USD","BK4550","SG9999002232.USD","LU0234572021.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999002224.SGD","SG9999013999.USD","BK4533","LU0306807586.USD","LU0289739699.SGD","SG9999001176.SGD","BK4007","BK4534","LU0225284248.USD","IE00BLSP4239.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2527230214","title":"诺和诺德盘中异动 大幅下挫3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527230214","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527230214?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 01:17","pubTimestamp":1744737463,"startTime":"0","endTime":"0","summary":"北京时间2025年04月16日01时17分，诺和诺德股票出现波动，股价快速下跌3.01%。截至发稿，该股报64.07美元/股，成交量359.287万股，换手率0.08%，振幅2.82%。诺和诺德股票所在的制药行业中，整体跌幅为0.05%。诺和诺德公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416011743aa2c7042&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416011743aa2c7042&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4532","LU1093756325.SGD","BK4588","LU0154236417.USD","LU1093756168.USD","BK4599","BK4007","BK4585","IE00BKVL7J92.USD","NVO"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":111,"code":"91000000","status":"200"}]}}